Gallo Daniel, Ruiz Agustín, Sánchez-Juan Pascual
Neurology Service, University Hospital Marqués de Valdecilla, Spain.
CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, 28220 Madrid, Spain; Research Center and Memory Clinic, Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, 08017 Barcelona, Spain.
Neuroscience. 2023 May 10;518:27-37. doi: 10.1016/j.neuroscience.2022.05.022. Epub 2022 May 21.
Primary Tauopathies are a group of diseases defined by the accumulation of Tau, in which the alteration of this protein is the primary driver of the neurodegenerative process. In addition to the classical syndromes (Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD)), new entities, like primary age-related Tauopathy (PART), have been recently described. Except for the classical Richardson's syndrome phenotype in PSP, the correlation between the clinical picture of the primary Tauopathies and underlying pathology is poor. This fact has challenged genetic studies. However, thanks to multicenter collaborations, several genome-wide association studies are helping us unravel the genetic structure of these diseases. The most relevant risk factor revealed by these studies is the Tau gene (MAPT), which, in addition to mutations causing rare familial forms, plays a fundamental role in sporadic cases of PSP and CBD in which there is a strong predominance of the H1 and H1c haplotypes. But outside of MAPT, several other genes have been robustly associated with PSP. These findings, pointing towards multifactorial causation, imply the participation of several pathways involving the myelin sheath integrity, the endoplasmic reticulum unfolded protein response, microglia, intracellular vesicle trafficking, or the ubiquitin-proteasome system. Additionally, GWAS show a high degree of genetic overlap across different Tauopathies. This is especially salient between PSP and CBD, but also GWAS studying the recently described PART phenotype shows genetic overlap with genes that promote Tau pathology and with others associated with Alzheimer's disease.
原发性 Tau 蛋白病是一组由 Tau 蛋白积聚所定义的疾病,其中这种蛋白质的改变是神经退行性过程的主要驱动因素。除了经典综合征(匹克病(PiD)、进行性核上性麻痹(PSP)、皮质基底节变性(CBD)和嗜银颗粒病(AGD))外,最近还描述了一些新的疾病实体,如原发性年龄相关性 Tau 蛋白病(PART)。除了 PSP 中的经典理查森综合征表型外,原发性 Tau 蛋白病的临床表现与潜在病理之间的相关性较差。这一事实给基因研究带来了挑战。然而,由于多中心合作,多项全基因组关联研究正在帮助我们揭示这些疾病的基因结构。这些研究揭示的最相关风险因素是 Tau 基因(MAPT),它除了导致罕见家族形式的突变外,在 PSP 和 CBD 的散发性病例中也起着重要作用,其中 H1 和 H1c 单倍型占主导地位。但在 MAPT 之外,还有其他几个基因与 PSP 密切相关。这些指向多因素病因的发现意味着涉及髓鞘完整性、内质网未折叠蛋白反应、小胶质细胞、细胞内囊泡运输或泛素 - 蛋白酶体系统的多种途径的参与。此外,全基因组关联研究显示不同 Tau 蛋白病之间存在高度的基因重叠。这在 PSP 和 CBD 之间尤为明显,而且研究最近描述的 PART 表型的全基因组关联研究也显示与促进 Tau 病理的基因以及与阿尔茨海默病相关的其他基因存在基因重叠。